BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制

doi:10.11904/j.issn.1002-3070.2022.05.011

Abstract

Abstract: Inhibition of apoptosis is a prominent feature of hematological malignancies.B-cell lymphoma-2(BCL-2)is a key protein regulator of apoptosis and is expressed to varying degrees in a variety of hematological malignancies.The anti-apoptotic ability of tumor cells with high expression of BCL-2 is significantly enhanced,and targeted inhibition of BCL-2 has become one of the research hotspots in anti-hematological tumors.Venetoclax(VEN)is the first BCL-2 inhibitor(BCL-2i)approved for the treatment of chronic lymphocytic leukemia,acute myeloid leukemia and myelodysplastic syndromes.Studies have shown that VEN also has antitumor activity against other hematological malignancies such as B-cell non-Hodgkin lymphomas and multiple myeloma.This article briefly reviews the anti-apoptosis mechanism of BCL-2,the clinical application of BCL-2i in hematological malignancies,and the possible mechanism of BCL-2i resistance.

Key words: B-cell lymphoma-2, Apoptosis, Venetoclax, Hematological malignancies

CLC Number:

R733

HE Xiaoqing, KE Peng, ZHANG Xinyou. The targeted therapy and mechanism of BCL-2 inhibitor in hematological malignancies[J]. Journal of Practical Oncology, 2022, 36(5): 452-457.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I5/452

References

1 Roberts AW.Therapeutic development and current uses of BCL-2 inhibition[J].Hematology,2020,2020(1):1-9.
2 Kale J,Osterlund EJ,Andrews DW.BCL-2 family proteins:changing partners in the dance towards death[J].Cell Death Differ,2018,25(1):65-80.
3 Valentin R,Grabow S,Davids MS.The rise of apoptosis:targeting apoptosis in hematologic malignancies[J].Blood,2018,132(12):1248-1264.
4 Ferrarini I,Rigo A,Visco C.The mitochondrial anti-apoptotic dependencies of hematologic malignancies:from disease biology to advances in precision medicine[J].Haematologica,2022,107(4):790-802.
5 Diepstraten ST,Anderson MA,Czabotar PE,et al.The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs[J].Nat Rev Cancer,2022,22(1):45-64.
6 Roberts AW,Wei AH,Huang DCS.BCL2 and MCL1 inhibitors for hematologic malignancies[J].Blood,2021,138(13):1120-1136.
7 Moia R,Patriarca A,Schipani M,et al.The biology of chronic lymphocytic leukemia:diagnostic and prognostic implications[J].Cancer J,2021,27(4):266-274.
8 Klein U,Lia M,Crespo M,et al.The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia[J].Cancer Cell,2010,17(1):28-40.
9 Stilgenbauer S,Eichhorst B,Schetelig J,et al.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion:a multicentre,open-label,phase 2 study[J].Lancet Oncol,2016,17(6):768-778.
10 Roberts AW,Davids MS,Pagel JM,et al.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J].N Engl J Med,2016,374(4):311-322.
11 Roberts AW,Ma S,Kipps TJ,et al.Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables[J].Blood,2019,134(2):111-122.
12 Seymour JF,Ma S,Brander DM,et al.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia:a phase 1b study[J].Lancet Oncol,2017,18(2):230-240.
13 Seymour JF,Kipps TJ,Eichhorst B,et al.Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[J].N Engl J Med,2018,378(12):1107-1120.
14 Al-Sawaf O,Zhang C,Tandon M,et al.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia(CLL14):follow-up results from a multicentre,open-label,randomised,phase 3 trial[J].Lancet Oncol,2020,21(9):1188-1200.
15 Jain N,Keating M,Thompson P,et al.Ibrutinib and venetoclax for first-line treatment of CLL[J].N Engl J Med,2019,380(22):2095-2103.
16 Hillmen P,Rawstron AC,Brock K,et al.Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia:the CLARITY study[J].J Clin Oncol,2019,37(30):2722-2729.
17 Deng J,Isik E,Fernandes SM,et al.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia[J].Leukemia,2017,31(10):2075-2084.
18 Ma S,Seymour JF,Brander DM,et al.Efficacy of venetoclax plus rituximab for relapsed CLL:5-year follow-up of continuous or limited-duration therapy[J].Blood,2021,138(10):836-846.
19 Izzo F,Landau DA.A BAX door to venetoclax resistance[J].Blood,2022,139(8):1124-1126.
20 Mato AR,Sharman JP,Biondo JML,et al.The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia:post-hoc analyses from the phase III MURANO study[J].Haematologica,2022,107(1):134-142.
21 Konopleva M,Pollyea DA,Potluri J,et al.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia[J].Cancer Discov,2016,6(10):1106-1117.
22 Lee JB,Khan DH,Hurren R,et al.Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production[J].Blood,2021,138(3):234-245.
23 Dinardo CD,Jonas BA,Pullarkat V,et al.Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J].N Engl J Med,2020,383(7):617-629.
24 Wei AH,Montesinos P,Ivanov V,et al.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy:a phase 3 randomized placebo-controlled trial[J].Blood,2020,135(24):2137-2145.
25 Chua CC,Roberts AW,Reynolds J,et al.Chemotherapy and venetoclax in elderly acute myeloid leukemia trial(CAVEAT):a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy[J].J Clin Oncol,2020,38(30):3506-3517.
26 Cherry EM,Abbott D,Amaya M,et al.Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia[J].Blood Adv,2021,5(24):5565-5573.
27 Dinardo CD,Pratz K,Pullarkat V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133(1):7-17.
28 Thijssen R,Diepstraten ST,Moujalled D,et al.Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias[J].Blood,2021,137(20):2721-2735.
29 Pei S,Pollyea DA,Gustafson A,et al.Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia[J].Cancer Discov,2020,10(4):536-551.
30 Davids MS,Roberts AW,Seymour JF,et al.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma[J].J Clin Oncol,2017,35(8):826-833.
31 Tam CS,Anderson MA,Pott C,et al.Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma[J].N Engl J Med,2018,378(13):1211-1223.
32 Davids MS,Roberts AW,Kenkre VP,et al.Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I,first-in-human study[J].Clin Cancer Res,2021,27(17):4690-4695.
33 Fowler N.BCL-2 inhibition in follicular lymphoma:Can we tip the scales?[J].Blood,2020,136(23):2598-2600.
34 Blombery P,Birkinshaw RW,Nguyen T,et al.Characterization of a novel venetoclax resistance mutation(BCL2 Phe104Ile)observed in follicular lymphoma[J].Br J Haematol,2019,186(6):e188-e191.
35 Morschhauser F,Feugier P,Flinn IW,et al.A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma[J].Blood,2021,137(5):600-609.
36 Touzeau C,Moreau P.Sensitivity to venetoclax:The B-side of myeloma?[J].Blood,2021,137(26):3582-3583.
37 Gupta VA,Barwick BG,Matulis SM,et al.Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression[J].Blood,2021,137(26):3604-3615.
38 Matulis SM,Gupta VA,Nooka AK,et al.Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax[J].Leukemia,2016,30(5):1086-1093.
39 Slomp A,Moesbergen LM,Gong JN,et al.Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting[J].Blood Adv,2019,3(24):4202-4214.

[1]	WEN Xiaoxing, LIU Dahai, WU Xuehui, WANG Bingping, FANG Tao. Knockdown osteopontin promotes gefitinib-resistence PC9 cells apoptosis [J]. Journal of Practical Oncology, 2022, 36(4): 310-315.
[2]	CHEN Xuejian, WANG Wei, ZHOU Jian, LI Ning, ZHANG Haopeng, XU Lishan. Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells [J]. Journal of Practical Oncology, 2021, 35(5): 408-413.
[3]	JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity [J]. Journal of Practical Oncology, 2021, 35(5): 462-467.
[4]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[5]	HU Qihui, DU Yichao, HE Kai, FU Wenguang, XIA Xianming. The role of endoplasmic reticulum stress in liver cancer [J]. Journal of Practical Oncology, 2021, 35(2): 160-164.
[6]	YIN Qi, HU Yanjian, CUI Puze, HU Yanhua. Research progress of Notch signaling pathway in regulating apoptosis of tumor cells [J]. Journal of Practical Oncology, 2021, 35(2): 165-169.
[7]	GUO Piaoting, MIN Li, CHEN Jianjun, WANG Xin, NI Siyi. Salvianolic acid B regulates ROS to inhibit the proliferation and promote apoptosis in colorectal cancer HCT-116 cells [J]. Journal of Practical Oncology, 2020, 34(6): 504-510.
[8]	HAN Jing, PU Yan, LIU Huibin. Effects of SKA1 on cell proliferation and apoptosis of renal cell carcinoma and its molecular mechanism [J]. Journal of Practical Oncology, 2020, 34(5): 404-411.
[9]	PANG Chen, ZHANG Xiuling, ZHANG Xiliu. Research progress in inhibitory epithelium-derived malignant tumors by dendrobium officinale [J]. Journal of Practical Oncology, 2020, 34(4): 362-367.
[10]	LUO Lifang,LIU Yunduo,GUAN Yue,CHEN Xiuwei. Quercetin-labeled metal organic framework radiotherapy combined with adriamycin induces apoptosis of cervical cancer HeLa cells [J]. Journal of Practical Oncology, 2020, 34(3): 203-207.
[11]	WANG Fei, ZHU Benben. Effects of propofol on the proliferation,apoptosis and invasion of SCC-74 cells via HIF-1 α signal pathway [J]. Journal of Practical Oncology, 2020, 34(2): 120-125.
[12]	ZENG Li, ZHUANG Shutong, DING Shihua, CHEN Chong, JIAO Lu, SUN Dayong. Molecular mechanisms of long non-coding RNA AFAP1-AS1 regulating the proliferation of colorectal cancer cells by PTEN/p-AKT signaling pathway [J]. Journal of Practical Oncology, 2020, 34(1): 11-16.
[13]	LI Chuanhai, LIU Yu, WANG Yanqun, CHEN Yingjian. The role and mechanism of ABL2 in lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 497-501.
[14]	HUANG Li, LONG Youmei, FU Yixia, XIA Liangbin. Effect of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells and its mechanism [J]. Journal of Practical Oncology, 2019, 33(6): 502-507.
[15]	CHEN Guanghao, FANG Jingxuan, PENG Sujuan, YAN Weiwei, WANG Fuhai, CHEN Chengzhe, CHEN Sichuan, PAN Jianji, QIU Sufang. Effects of PNCK on proliferation and apoptosis of nasopharyngeal carcinoma cells [J]. Journal of Practical Oncology, 2019, 33(5): 397-401.

The targeted therapy and mechanism of BCL-2 inhibitor in hematological malignancies

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments